Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 1,836 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo- C Clear all
Withdrawn Not applicable Interventional

Treatment of Postoperative Pain After Total Knee Arthroplasy Using Intravenous Lidocaine Infusion

NCT00616850
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Continuous femoral catheter block, Lidocaine, Preservative free normal saline
Procedure · Drug · Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 31, 2026, 10:54 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants

NCT07075640
View directory record Official record
Conditions
Healthy Participants
Interventions
AG-236, Placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 31, 2026, 10:54 PM EDT
Completed Phase 3 Interventional Results available

Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

NCT01004978
View directory record Official record
Conditions
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Interventions
Cisplatin, Computed Tomography, Doxorubicin Hydrochloride, Doxorubicin-Eluting Beads, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Mitomycin, Pharmacological Study, Placebo Administration, Sorafenib Tosylate
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
281
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 183 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Oct 31, 2026, 10:54 PM EDT
Completed Phase 2 Interventional Results available

The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis

NCT04134091
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
LPCN 1144 Formulation A, LPCN 1144 Formulation B, Placebo
Drug
Lead sponsor
Lipocine Inc.
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
19
States / cities
El Cajon, California • Murrieta, California • Rialto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 31, 2026, 10:54 PM EDT
Completed Phase 2 Interventional Results available

MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)

NCT01643850
View directory record Official record
Conditions
Pigmented Villonodular Synovitis, PVNS, Giant Cell Tumor of the Tendon Sheath, GCCTS, Tenosynovial Giant Cell Tumor Localized or Diffused Type, GCTS
Interventions
MCS110, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
7
States / cities
San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 31, 2026, 10:54 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia

NCT01644474
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Ezetimibe, Placebo (for Alirocumab), Placebo (for Ezetimibe)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Overland Park, Kansas • Cincinnati, Ohio • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Oct 31, 2026, 10:54 PM EDT
Completed Phase 1 Interventional

Alleviation of Common Cold Symptoms

NCT06106880
View directory record Official record
Conditions
Common Cold, Pharyngitis, Fever, Congestion, Rhinorrhea, Cough, Sore-throat, Sore Throats Viral, Malaise, Headache, Runny Nose, Sneezing
Interventions
Wintergreen Throat Spray and Aspirin Tablet, Aspirin Throat Spray and Placebo Tablet, Wintergreen Throat Spray and Placebo Tablet, Placebo Throat Spray and Placebo Tablet
Drug · Dietary Supplement · Other
Lead sponsor
Applied Biological Laboratories Inc
Other
Eligibility
18 Years to 65 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
6
States / cities
Irvine, California • Washington D.C., District of Columbia • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 31, 2026, 10:54 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

NCT07063745
View directory record Official record
Conditions
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Interventions
BMS-986504, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
44
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 31, 2026, 10:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)

NCT01453075
View directory record Official record
Conditions
Chronic Hepatitis C Infection
Interventions
Valacyclovir, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 31, 2026, 10:54 PM EDT
Not listed Not applicable Interventional

A Cognitive Bias Modification RCT for Aggression

NCT04819230
View directory record Official record
Conditions
Intermittent Explosive Disorder
Interventions
Cognitive Bias Modification, Cognitive Bias Control
Behavioral
Lead sponsor
Temple University
Other
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 31, 2026, 10:54 PM EDT
Completed Phase 2 Interventional Results available

A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

NCT03751657
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Placebo (insulin 287), Metformin, Dipeptidyl peptidase-4 inhibitors, Insulin glargine, Placebo (insulin glargine)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
14
States / cities
Lancaster, California • Ventura, California • Walnut Creek, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 31, 2026, 10:54 PM EDT
Completed Phase 2Phase 3 Interventional Results available

The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)

NCT01923428
View directory record Official record
Conditions
Constipation Predominant Irritable Bowel Syndrome
Interventions
AZD1722, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 75 Years
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Boulder, Colorado • Greensboro, North Carolina • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Oct 31, 2026, 10:54 PM EDT
Completed Phase 3 Interventional Results available

Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)

NCT04394351
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Dupilumab, Matching Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
1 Year to 11 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 31, 2026, 10:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis

NCT03922607
View directory record Official record
Conditions
Psoriasis
Interventions
ABBV-157, Placebo for ABBV-157
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 31, 2026, 10:54 PM EDT
Completed Phase 2 Interventional Results available

Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT00460811
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation
Interventions
Linaclotide Acetate, Matching placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
79
States / cities
Huntsville, Alabama • Chandler, Arizona • Tuscon, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 31, 2026, 10:54 PM EDT
Withdrawn Phase 2 Interventional

ACZ885 in Type 1 Diabetes Mellitus

NCT01322321
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Type 1
Interventions
ACZ885, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 35 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 5, 2012 · Synced Oct 31, 2026, 10:54 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Study Evaluating the Impact of Regular FODMAP-targeting Digestive Enzyme Blend Use on Gastrointestinal Symptoms in Individuals With Self-Reported Bloating

NCT07591584
View directory record Official record
Conditions
IBS (Irritable Bowel Syndrome), Bloating, Abdominal Pain, Gut Health
Interventions
FODMAP-targeting digestive enzyme blend, Placebo
Dietary Supplement · Other
Lead sponsor
Kiwi Health Inc
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 31, 2026, 10:54 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY3867070 in Healthy Participants

NCT07021547
View directory record Official record
Conditions
Healthy
Interventions
LY3867070, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Anaheim, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 31, 2026, 10:54 PM EDT
Completed Phase 3 Interventional

Prevention of Recurrent Aphthous Stomatitis Using Vitamins

NCT00527306
View directory record Official record
Conditions
Aphthous Stomatitis
Interventions
multivitamin
Dietary Supplement
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Oct 31, 2026, 10:54 PM EDT
Terminated Phase 2 Interventional Results available

Study in Hepatitis C Virus (HCV) Infected Patients Undergoing Liver Transplantation to Evaluate a Human Monoclonal Antibody Against Hepatitis C

NCT01121185
View directory record Official record
Conditions
HCV Infection, Liver Transplantation
Interventions
MBL-HCV1, 0.9% Sodium chloride Placebo
Biological · Other
Lead sponsor
MassBiologics
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
New Haven, Connecticut • Boston, Massachusetts • Burlington, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2016 · Synced Oct 31, 2026, 10:54 PM EDT
Completed Phase 2 Interventional

A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease

NCT03677648
View directory record Official record
Conditions
Crohn's Disease
Interventions
SHR0302, Placebos
Drug
Lead sponsor
Reistone Biopharma Company Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Clearwater, Florida • Lake Wales, Florida • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 31, 2026, 10:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Hemodynamic Response to to a Sublingual Dose of Glyceryl Trinitrate in Subjects Receiving TA-1790, Sildenafil Citrate, and Placebo

NCT01616485
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
TA-1790, Sildenafil citrate, Placebo, Nitrostat
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
30 Years to 60 Years · Male only
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Oct 31, 2026, 10:54 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C

NCT05975021
View directory record Official record
Conditions
Cardiogenic Shock
Interventions
Istaroxime, Placebo
Drug
Lead sponsor
Windtree Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 31, 2026, 10:54 PM EDT
Completed Phase 2 Interventional

Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery

NCT04877756
View directory record Official record
Conditions
Hypertrophic Scar
Interventions
OLX10010
Drug
Lead sponsor
Olix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Miami, Florida • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 31, 2026, 10:54 PM EDT